| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,500 | 4,660 | 13:02 | |
| 4,400 | 4,580 | 23.12. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.12. | Abeona Therapeutics beruft Mohamad Tabrizi zum Chief Business Officer | 4 | Investing.com Deutsch | ||
| 15.12. | Abeona Therapeutics appoints Mohamad Tabrizi as chief business officer | 2 | Investing.com | ||
| 15.12. | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | 197 | GlobeNewswire (Europe) | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| 11.12. | Abeona Therapeutics Inc.: Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in Texas | 1 | GlobeNewswire (USA) | ||
| 08.12. | Abeona Therapeutics Inc.: Abeona Therapeutics Announces First Patient Treatment with ZEVASKYN Gene Therapy | 193 | GlobeNewswire (Europe) | CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a... ► Artikel lesen | |
| 01.12. | Abeona Therapeutics Inc.: Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| ABEONA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.11. | Stifel lowers Abeona Therapeutics stock price target on launch delay | 17 | Investing.com | ||
| 12.11. | Abeona Therapeutics Shares Jump 21% On Strong Q3 Results | 9 | RTTNews | ||
| 12.11. | Here's Why Abeona Therapeutics Popped Higher Today | 19 | The Motley Fool | ||
| 12.11. | Abeona Therapeutics: EPS übertrifft Schätzungen um 0,17 $ - Umsatz schlechter als erwartet | 13 | Investing.com Deutsch | ||
| 12.11. | Abeona Therapeutics GAAP EPS of -$0.10 beats by $0.18 | 4 | Seeking Alpha | ||
| 12.11. | Abeona Therapeutics Inc.: Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates | 293 | GlobeNewswire (Europe) | - First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with... ► Artikel lesen | |
| 12.11. | ABEONA THERAPEUTICS INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | ABEONA THERAPEUTICS INC. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | What to Expect from Abeona Therapeutics' Earnings | 2 | Benzinga.com | ||
| 11.11. | Abeona Therapeutics Q3 2025 Earnings Preview | 2 | Seeking Alpha | ||
| 03.11. | Abeona Therapeutics Inc.: Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 30.10. | Abeona Therapeutics stock rises after receiving permanent J-code for ZEVASKYN | 7 | Investing.com | ||
| 30.10. | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Permanent J-Code for ZEVASKYN (prademagene zamikeracel) | 390 | GlobeNewswire (Europe) | CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced... ► Artikel lesen | |
| 20.10. | Abeona Therapeutics appoints Dr. James Gow to lead clinical development | 8 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,50 | +3,14 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| EVOTEC | 5,388 | +3,10 % | Wochenende-Spezial: Evotec-Aktie polarisiert - kommt am Montag die Überraschung? | ||
| BB BIOTECH | 49,200 | -0,10 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| MEDIGENE | 0,025 | +16,67 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 38,985 | -0,35 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| CUREVAC | 3,478 | +1,70 % | Wochenend-Update: Curevac-Aktie im Fokus - was Anleger jetzt wissen müssen! | ||
| MODERNA | 27,580 | -9,19 % | Forget Moderna Stock, This is a Much Better Buy | ||
| VALNEVA | 3,654 | -1,77 % | Samstags-Check: Valneva-Aktie sorgt für Gesprächsstoff - wie geht es Montag weiter? | ||
| AMGEN | 279,55 | -0,50 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| EPIGENOMICS | 0,890 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 5,766 | -2,24 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 301,70 | -0,59 % | Stryker Earnings Preview: What to Expect | ||
| BIOGEN | 146,80 | -2,23 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,310 | -0,43 % | EQS-News: Heidelberg Pharma AG: Brief des Vorstandsvorsitzenden | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma: Brief des Vorstandsvorsitzenden
17.12.2025 / 09:21 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| ILLUMINA | 114,98 | -1,42 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen |